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INTRODUCTION
Chronic insomnia and obstructive sleep apnea (OSA) are 
two of the most common sleep disorders. Several studies have 
documented extensive comorbidity with these disorders, with 
the prevalence of insomnia symptoms in patients with OSA 
(40-60%) far exceeding that in the general population.1-6 When 
these disorders coexist, not only is there an increase in cumula-
tive morbidity, but it is likely that these two diseases interact 
to promote overall greater illness severity and influence each 
other in negative ways.3 Further, the co-occurrence of OSA and 
insomnia symptoms may complicate OSA treatment and reduce 
PAP adherence. Recent reviews have called for more research 
on the comorbidity between insomnia and OSA.7-10
Insomnia is not, however, a homogenous disorder. There are 
a variety of types and subtypes. The subtypes of insomnia are 
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typically characterized as difficulties initiating sleep (initial 
insomnia), difficulties maintaining sleep (middle insomnia), 
and early morning awakenings (late insomnia).1 OSA may 
serve as a predisposing and/or a precipitating factor for each 
of the subtypes of insomnia. It also may be the case that one 
or more of the insomnia subtypes respond differently to OSA 
treatment and/or are associated with different levels of OSA 
treatment adherence.
Treatment with positive airway pressure (PAP) is the first-
line treatment for OSA, but it can be difficult for patients to 
tolerate PAP and studies have shown that as few as 50% of 
patients adhere to the treatment over time.11,12 Currently, few 
studies have (1) assessed the relative prevalence of insomnia 
subtypes in patients with OSA, (2) explored how PAP affects 
insomnia that is comorbid with OSA (both overall and by 
subtype), and (3) evaluated how insomnia affects PAP adher-
ence. Of the studies that exist, the findings are mixed.13-15 
Nguyen et al.13 showed that even though insomnia symptoms 
were highly prevalent among patients with OSA, they had no 
effect on PAP adherence. In contrast, Wickwire et al.14 showed 
that symptoms of middle insomnia were related to poor PAP 
adherence; in addition, a recent study by Pieh et al.15 found a 
negative effect of psychological factors related to insomnia 
symptoms on PAP adherence.
SLEEP, Vol. 36, No. 12, 2013 1902 Insomnia Symptoms and OSA—Björnsdóttir et al
In our previous study,2 we found that most patients with 
untreated OSA had symptoms of middle insomnia but the 
prevalence of initial insomnia was the same as in the general 
population. Another study found symptoms of middle insomnia 
to be the most common subtype among patients with OSA.16 
Theoretically, it is surprising that patients with OSA might find 
it difficult to fall asleep at night because excessive daytime 
sleepiness (EDS) is a common symptom of untreated OSA. 
However, it seems likely that repeated breathing disturbances 
could result in sleep fragmentation and hence middle or late 
insomnia. Therefore, patients who wake up frequently because 
of apneic episodes may experience more refreshing sleep when 
using PAP and as a result adjust favorably to the treatment. 
Initial insomnia may be expected to diminish adherence to 
PAP because patients are awake longer and thus more likely to 
experience the adverse aspects of this treatment (e.g., mask or 
airflow discomfort) for longer periods of time.12
The purpose of the current study was to compare the prev-
alence of symptoms of initial, middle, and late insomnia in 
patients with OSA prior to and following the start of PAP treat-
ment, as well as to explore the changes in insomnia symptoms 
by subtype in individuals who were or were not using PAP 
at follow-up. It was hypothesized that symptoms of middle 
insomnia would have the strongest association with untreated 
OSA and would therefore improve significantly among patients 
on PAP treatment. However, we expected that symptoms of 
initial and late insomnia would be more resistant to change 
despite successful treatment of OSA and that patients with these 
symptoms would more likely not be using PAP at follow-up.
PATIENTS AND METHODS
Patients in whom OSA had been diagnosed in Iceland and 
who were referred for PAP treatment to Landspitali—The 
National University Hospital of Iceland in Reykjavik (the 
only site in Iceland providing PAP treatment) from September 
2005 through December 2009 were invited to participate in 
the study. They are part of the Icelandic Sleep Apnea Cohort 
(ISAC).3 OSA had been recently diagnosed in all enrolled partic-
ipants (minimum apnea-hypopnea index [AHI] of 15 events/h) 
and these patients were about to begin PAP treatment. Two y 
after treatment initiation, participants were invited for a follow-
up visit where treatment adherence was examined and baseline 
assessments were repeated.
Questionnaire and Procedures
All participants were invited to the outpatient clinic at Land-
spitali—The National University Hospital of Iceland in Reyk-
javik. The study was approved by Iceland´s National Bioethics 
Committee, the Data Protection Authority of Iceland, and the 
Institutional Review Board of the University of Pennsylvania. 
After a written informed consent was obtained from the research 
participants, they answered standardized questionnaires about 
their health and sleep. Additional details are provided in the 
study by Bjornsdottir et al.2
Insomnia Definition
Insomnia symptoms were defined using answers to three 
questions from the Basic Nordic Sleep Questionnaire. “I have 
difficulties falling asleep at night” (initial insomnia), “I wake up 
often during the night” (middle insomnia), and “I wake up early 
in the morning and can’t fall back asleep” (late insomnia).17 
Patients were not asked to refer to a specific time period when 
answering these questions. Answers were rated on a five-point 
scale: never/almost never (1); less than once a week (2); once 
or twice a week (3); three to five times a week (4); every day or 
almost every day of the week (5). Those who scored ≥ 4 on one 
or more of these items were defined as having insomnia of that 
subtype. A patient with insomnia could be classified as having 
one or more subtype.
Quality of Life
Participants completed the 12-Item Short Form Health 
Survey (SF-12) questionnaire to assess quality of life. Two 
summary component scores were derived from the SF-12: 
physical and mental health summary scores.18 These scores 
range from 0-100, where a score of zero indicates the lowest 
life quality and 100 indicates the highest life quality.
Excessive Daytime Sleepiness
Daytime sleepiness was evaluated using the Epworth Sleepi-
ness Scale (ESS), a brief questionnaire that measures daytime 
sleepiness.19 Participants with ESS score ≥ 10 were considered 
to have excessive daytime sleepiness.
Sleep Apnea Assessment
All participants had a sleep study while untreated with a 
type 3 portable sleep monitor (Natus Medical Inc, San Carlos, 
CA, USA or NoxMedical, Reykjavik, Iceland). The same 
signals were recorded by each monitor. To test for systematic 
differences in the measurement of OSA severity by the Embla 
(available from Natus Medical) versus NoxMedical monitors, 
simultaneous overnight recordings were obtained in 12 patients. 
No significant differences were found in the AHI or oxygen 
desaturation index (ODI) measured with the different devices. 
A two-way random effect model for Intraclass Correlation 
Coefficient (ICC) for consistency showed that the ICC for AHI 
was 0.99 (P < 0.001) and the ICC for ODI was 0.97 (P < 0.001).
The sleep recordings were rescored in a uniform manner by 
a centralized scoring laboratory using the Somnologica Studio 
(Natus) software. Scoring of a hypopnea required a ≥ 30% 
decrease in airflow with ≥ 4% oxygen desaturation or a ≥ 50% 
decrease in airflow for ≥ 10 sec with a sudden increase in flow 
at the end of the event. Scoring of an apnea required a ≥ 80% 
decrease in flow for ≥ 10 sec. The ODI was calculated as the 
number of falls in oxygen saturation of ≥ 4% per h of recording. 
Additional details are provided in the study by Arnardottir et al.20
PAP Use
All patients prescribed PAP were taken care of at the 
Department of Respiratory Medicine and Sleep, Landspitali 
University Hospital. Patients on PAP had direct access to the 
outpatient clinic where trained staff helped them to find the 
type of device and settings they needed. Various mask types 
and heated humidifiers were available. PAP users were all in a 
constantly updated register and they paid a monthly service fee.
PAP adherence at follow-up was estimated based on down-
loads of usage in the previous 4 w from memory cards (objec-
tive data), if available, from ResMed S8 machines (ResMed 
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Corp. San Diego, CA, USA). Some patients had older PAP 
devices that did not allow for this type of download. Self-
reported data from all patients (subjective data) was also 
collected at the follow-up visit, based on three multiple choice 
questions about average PAP use: (1) Do you use PAP for your 
sleep apnea? (Response alternatives: yes, no, or don’t know) (2) 
How many nights/w do you use PAP? (Response alternatives: 
1, 2, 3, 4, 5, 6, or 7 nights/w) and 3) How much of the sleeping 
time each night do you use PAP? (Response alternatives: all the 
sleeping time [100%]; almost all the sleeping time [80-99%]; 
most of the sleeping time [60-79%]; about half of the sleeping 
time [40-59%], about one third of the sleeping time [20-39%]; 
almost none of the sleeping time [1-19%]; none of the sleeping 
time [0%]; don´t know).
Statistical Analyses
All statistics were calculated with STATA 11.0 for Windows 
(Stata Corporation, College Station, TX, USA). Change in the 
prevalence of insomnia symptoms with PAP treatment was 
estimated using population-averaged generalized estimating 
equations for binomial outcome. The Wald test was used to 
examine differences in change of prevalence by level of PAP 
use. Logistic regression was used to analyze risk factors for 
PAP nonusers at follow up. A P value ≤ 0.05 was deemed statis-
tically significant.
RESULTS
Population Characteristics
At baseline, 822 patients with untreated OSA were enrolled 
in the study and 90% (n = 741) came to the 2-y follow-up 
(average ± standard deviation [SD] time between baseline and 
follow-up visit was 774 ± 135 days). Of these patients, three did 
not answer the insomnia questions and were therefore excluded 
from the analyses. In addition, 33 were excluded because they 
were using a mandibular device instead of PAP at the follow-
up. The final study cohort was therefore n = 705 
(568 males [80.6%] and 137 females [19.4%]). 
Additional details are presented in Figure 1.
There was no baseline difference in the distribu-
tion of insomnia symptoms, OSA severity, or other 
main characteristics between the 117 patients who 
were excluded or did not finish the follow-up and 
the final study cohort.
Table 1 provides the baseline characteristics of 
the study population while untreated. The women 
were on average 4 y older and were more likely to 
report symptoms of initial insomnia.
Prevalence of Insomnia at Baseline
The prevalence of the three different insomnia 
subtypes was assessed prior to and 2 y after starting 
PAP treatment. At baseline, 15.5% of patients 
exhibited symptoms of initial insomnia, 59.3% 
had symptoms of middle insomnia, and 27.7% 
exhibited symptoms of late insomnia. The preva-
lence of having some type of insomnia symptoms 
at baseline was 68.3%, but there was consider-
able overlap between the three different insomnia 
subtypes, with most patients having more than one symptom of 
insomnia (Figure 2). Almost half of those who had symptoms 
of initial insomnia at baseline also had symptoms of middle and 
late insomnia. Most of those with symptoms of late insomnia 
at baseline also had symptoms of middle insomnia. Interest-
ingly, most of those with symptoms of middle insomnia did not 
present with one or the other subtypes. As a result, 33% of the 
sample had symptoms of isolated middle insomnia at baseline 
Figure 1—Flow chart of participants.
The Icelandic Sleep Apnea Cohort (ISAC) 
Baseline
All subjects n = 822
• Death n = 7
• Living abroad n = 13
• Declined participation 
in follow-up n = 61
• Did not answer 
insomnia questions 
n = 3
• Were using 
mandibular device 
instead of PAP n = 33
ISAC 2 year follow-up
All subjects n = 705
Nonusers
n = 232
CPAP users
n = 473
Table 1—Baseline characteristics of the study population
All patients 
(n = 705)
Men
(n = 568)
Women 
(n = 137)
P value for sex 
difference
Age 54.9 ± 10.2 54.1 ± 10.3 58.4 ± 8.9 < 0.001
Body mass index 33.7 ± 5.6 33.6 ± 5.5 32.3 ± 6.0 0.18
AHI 45.5 ± 20.5 46.0 ± 20.5 43.1 ± 20.4 0.15
ODI 36.3 ± 20.0 36.9 ± 19.8 33.9 ± 20.8 0.12
ESS 11.9 ± 5.0 11.9 ± 5.0 11.7 ± 5.3 0.60
Smoking history 
Never smoker 27.3% 26.0% 30.7% 0.27
Ex-smoker 53.0% 53.3% 51.8% 0.76
Current smoker 20.1% 20.7% 17.5% 0.40
Hypertension 46.5% 45.5% 50.4% 0.30
Diabetes 8.5% 8.6% 8.1% 0.84
Initial insomnia 15.5% 12.5% 27.9% < 0.001
Middle insomnia 59.3% 57.8% 65.7% 0.09
Late insomnia 27.7% 26.6% 32.1% 0.20
AHI, apnea-hypopnea index; ESS, Epworth Sleepiness Scale score; ODI, oxygen 
desaturation index. Significance is indicated in bold.
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and these patients were more obese, had more severe OSA 
(i.e., a higher AHI) and better mental quality of life compared 
with patients with other symptoms of insomnia (initial, late, or 
mixed insomnia) (Table 2).
PAP Use and Estimate of Adherence
Among the 705 patients who completed the follow-up, 
473 reported current PAP use and 232 reported being nonusers. 
Objective data were available for 77.6% of PAP users (367 of 
473), and based on these data the average (± SD) use per night 
was 6.2 (± 2.0) h for the last 4 w. Only 46 of those individuals 
used the device less than 4 h per night on average. At baseline 
all patients were prescribed automatic positive airway pressure 
(autoPAP) and treatment was changed to continuous positive 
airway pressure (CPAP) if the pressure requirements over the 
night were stable. Of the PAP users, 53% were on autoPAP and 
43% were on fixed CPAP, 3% on bilevel pressure (BiPAP), and 
1% on adaptive servoventilation. Treatment was only changed 
to BiPAP or adaptive servoventilation if treatment efficacy was 
inadequate. The average (± SD) PAP pressure was 10.9 (± 1.5) 
cm H2O and the pressure below which participants on autoPAP 
spent 95% of the time over the last 7 days was 11.1 (± 1.9) 
cm H2O.
Full Versus Partial Users
Patients using PAP for ≥ 5 days/w and ≥ 4 h/night on average 
for the past 4 w were considered full users (n = 287 of 367 with 
objective data). On average, full users were using their device 
for 26.7 ± 2.0 nights for the last 4 w and 6.8 ± 1.2 h per night 
based on objective data.
Among the 367 with both objective (memory cards) and self-
reported data on frequency of CPAP use, we compared those 
reporting PAP usage ≥ 5 nights/w and ≥ 60% of the night with 
those fulfilling criteria for full PAP use based on memory cards 
(≥ 5 days/w and ≥ 4 h/night). Self-reported data had 98.6% 
sensitivity and 45.1% specificity in distinguishing full versus 
partial users. Consequently, objective data were used when 
available, but for the remaining patients, the self-reported data 
were used to define patients as full, partial, and non-PAP users. 
Therefore, a total of n = 372 were classified as full users and 
n = 101 as partial users (367 and 106 were classified based on 
objective and subjective data, respectively).
On average, partial users were using their device for 
14.3 ± 7.2 nights for the last 4 w and 3.5 ± 2.2 h per night (for 
all 28 nights) based on objective data.
Among the 232 nonusers, n = 60 (26.0%) returned their 
devices within 3 mo from starting PAP. Most of the nonusers 
(n = 133) had a repeat sleep study at the 2-y follow-up. On 
average, AHI in these individuals increased from baseline 
to follow-up (mean increase ± SD = 10.7 ± 22.2 events per 
hour). There were 98% of the 133 patients who still had an 
AHI > 15 at the 2-y follow-up. A few of the nonusers (n = 11) 
had lost more than 10 kg from baseline to follow-up but they 
were not different in insomnia status or OSA severity at follow-
up compared with that at baseline. Of these 11 patients, seven 
had a repeat sleep study at follow-up and they were all still 
affected with OSA (AHI ≥ 15) despite their weight loss. In total, 
the nonusers (n = 133) lost on average 0.2 ± 8.2 kg from base-
line to follow-up.
The primary analyses of this paper were conducted by 
comparing all PAP users (full and partial) with nonusers. Addi-
tional sensitivity analysis was performed by assessing the three 
use designations for group differences (full users, partial users, 
and nonusers). Using three groups of PAP users did not affect 
the significance of the results. Partial users were not signifi-
cantly different from full users and therefore we used only two 
groups for analysis, all PAP users and nonusers. Furthermore, 
all analysis were repeated using only PAP users with objective 
data (n = 367), which did not affect the significance of any of 
the results.
Changes in Insomnia Symptoms from Baseline to Follow-up 
among PAP Users and Nonusers
Symptoms of Initial Insomnia
The baseline prevalence of symptoms of initial insomnia was 
12.9% among those who were PAP users at follow-up, compared 
with 20.8% among nonusers (P = 0.007). At follow-up, 9.3% 
Figure 2—Baseline prevalence of insomnia symptoms among all 
patients.
Table 2—Baseline differences between those with isolated middle 
insomnia and those with other symptoms of insomnia (initial, late or 
mixed)
Isolated middle 
insomnia (n = 244)
Other type of 
insomnia (n = 258) P value
Age 55.2 ± 10.7 55.5 ± 9.6 0.77
BMI 34.2 ± 6.1 33.1 ± 5.5 0.04
AHI 48.4 ± 21.1 41.6 ± 20.0 < 0.001
ODI 39.1 ± 21.2 32.5 ± 18.2 < 0.001
ESS 12.5 ± 5.0 11.8 ± 5.0 0.11
SF-12 PS 39.3 ± 11.1 39.0 ± 11.0 0.77
SF-12 MS 49.1 ± 10.0 45.7 ± 11.2 < 0.001
AHI, apnea-hypopnea index; BMI, body mass index; ESS, Epworth 
Sleepiness Scale score; ODI, oxygen desaturation index; SF-12 MS, 
mental quality of life; SF-12 PS, physical quality of life. Significance is 
indicated in bold.
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of PAP users had symptoms of initial insomnia compared with 
17.7% of nonusers (P = 0.001). Improvement in these symp-
toms from baseline to follow-up was of the same magnitude for 
PAP users and nonusers (Table 3 and Figure 3).
In total, 45.9% of those who had symptoms of initial 
insomnia at baseline also had these symptoms at follow-up. 
However, there was no baseline difference in regard to age, 
body mass index (BMI), or OSA severity between those whose 
initial insomnia improved and those with persistent symptoms 
of initial insomnia. There was, however, more improvement in 
daytime sleepiness among those without symptoms of initial 
insomnia at follow-up (Table 4).
Patients who reported symptoms of initial insomnia at base-
line were more likely to be PAP nonusers at follow-up and this 
effect remained significant after adjusting for age, sex, BMI, 
smoking, and OSA severity (Table 5).
Figure 3—The changes and overlap of insomnia subtypes for both positive airway pressure (PAP) users and nonusers.
Table 3—The difference in changes of insomnia symptoms from baseline 
to follow-up between positive airway pressure users and nonusers
Baseline (%) Follow-up (%) Pchange P*
Initial insomnia 
Nonusers 20.8 17.7 0.25
PAP users 12.9 9.3 0.03 0.75
Middle insomnia
Nonusers 59.1 43.5 < 0.001
PAP users 59.4 30.7 < 0.001 0.001
Late insomnia
Nonusers 36.6 26.0 0.001
PAP users 23.3 21.2 0.34 0.05
*P for difference in change between PAP users and nonusers. PAP, 
positive airway pressure. Significance is indicated in bold.
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Symptoms of Middle Insomnia
The baseline prevalence of middle insomnia symptoms was 
59.1% among those who were PAP users at follow-up compared 
with 59.4% among nonusers (P = 0.93). Compared with base-
line, there was a significant improvement in symptoms of 
middle insomnia for both PAP users and nonusers at follow-up 
(follow-up prevalence was 30.7% among PAP users compared 
with 43.5% among nonusers; P ≤ 0.001). However, improve-
ment in these symptoms was much more likely to occur among 
patients who were adherent with PAP treatment (P = 0.001 for 
difference in change between PAP users and nonusers). See 
Table 3 and Figure 3 for details.
Patients whose middle insomnia improved (as compared 
with those with persistent symptoms of middle insomnia) were 
younger, more obese, and had more severe OSA at baseline (Table 
6). There was also greater improvement in physical quality of life 
and daytime sleepiness among those patients (Table 4).
Having symptoms of middle insomnia overall did not 
affect PAP adherence, but individuals with symptoms of 
isolated middle insomnia were 
more likely to be PAP users at 
follow-up and the effect remained 
significant after adjusting for 
age, sex, BMI, smoking, and 
OSA severity (Table 5).
Symptoms of Late Insomnia
The baseline prevalence of 
having symptoms of late insomnia 
was 23.3% among those who were 
PAP users at follow-up compared 
with 36.6% among nonusers 
(P < 0.001). Nonusers were more 
likely to experience improvement in late insomnia compared 
with PAP users (P = 0.05), improving to levels comparable 
to those of PAP users (PAP users: 21.2%, nonusers: 26%) 
(Table 3 and Figure 3).
In total, 46.7% of those who had symptoms of late 
insomnia at baseline also had these symptoms at follow-
up, but there was no baseline difference in regard to age, 
BMI, or OSA severity between those whose late insomnia 
improved compared with those with persistent symptoms of 
late insomnia. Patients whose late insomnia improved did, 
however, show a greater improvement in mental quality of 
life and daytime sleepiness (Table 4).
Patients who reported symptoms of late insomnia at base-
line were more likely to be PAP nonusers at follow-up and this 
effect remained significant after adjusting for age, sex, BMI, 
smoking, and OSA severity (Table 5).
When looking at how long the mask is worn based on objec-
tive PAP data, PAP users with symptoms of late insomnia 
at follow-up had on average 36 min shorter mask-on time 
than those without late insomnia (P = 0.02). This differ-
ence in mask-on time was not seen for patients with other 
types of insomnia.
No Insomnia Symptoms
Having no symptoms of insomnia at baseline was equally 
prevalent among those who were PAP users and nonusers at 
follow-up (PAP users: 33.3%, nonusers: 28.5%, P = 0.20). At 
follow-up, 55.7% of PAP users had no insomnia compared with 
47.4% of nonusers (P = 0.04). Most patients who reported no 
symptoms of insomnia at baseline were also without insomnia 
symptoms at follow-up. However, 22.4% of them reported 
some insomnia symptoms at follow-up. Developing symp-
toms of middle and late insomnia were much more prevalent 
Table 4—Change in daytime sleepiness and quality of life among those whose insomnia improved and persisted
Initial insomnia Middle insomnia Late insomnia
persisted 
(n = 50)
improved 
(n = 59) P 
persisted 
(n = 199)
improved 
(n = 219) P
persisted 
(n = 91)
improved 
(n = 103) P 
ESS change -1.0 ± 4.3 -3.5 ± 4.8 0.006 -2.6 ± 4.5 -4.6 ± 5.0  < 0.001 -1.8 ± 4.8 -3.9 ± 4.5 0.002
SF-12 MS change -0.5 ± 10.2 1.5 ± 9.9 0.34 1.3 ± 10.0 3.5 ± 9.4 0.02 1.4 ± 10.6 2.9 ± 10.0 0.29
SF-12 PS change 3.0 ± 14.3 2.2 ± 13.9 0.78 2.5 ± 11.8 3.3 ± 11.8 0.48 0.3 ± 12.3 4.2 ± 11.7 0.03
ESS, Epworth Sleepiness Scale; SF-12 MS, mental quality of life; SF-12 PS, physical quality of life. Significance is indicated in bold.
Table 5—Unadjusted and adjusted effects of insomnia symptoms on PAP nonuse
Unadjusted odds 
ratio (95% CI) P value
Adjusted odds ratio 
(95% CI)a P valuea
Initial insomnia (n = 109) 0.56 (0.37-0.86) 0.007 0.59 (0.38-0.91) 0.01
Middle insomnia (n = 418) 1.01 (0.73-1.40) 0.93 0.98 (0.70-1.37) 0.89
Late insomnia (n = 194) 0.53 (0.37-0.74) < 0.001 0.55 (0.39-0.79) < 0.001
Isolated middle insomnia (n = 244) 1.61 (1.14-2.27) 0.007 1.48 (1.04-2.12) 0.03
aAdjusted for sex, age, body mass index, and obstructive sleep apnea severity (apnea-hypopnea index and 
oxygen desaturation index). Significance is indicated in bold. CI, confidence interval; PAP, positive airway 
pressure.
Table 6—Baseline characteristics among those whose middle insomnia 
symptoms improved and persisted
Middle insomnia 
persisted (n = 199)
Middle insomnia 
improved (n = 219) P value
Male (%) 81.0 76.3 0.23
Age 57.3 ± 9.4 54.8 ± 10.2 0.01
BMI 32.8 ± 5.1 35.1 ± 6.4  < 0.001
AHI 43.4 ± 20.1 47.3 ± 20.9 0.05
ODI 33.3 ± 18.5 39.9 ± 20.5  < 0.001
AHI, apnea-hypopnea index; BMI, body mass index; ODI, oxygen 
desaturation index. Significance is indicated in bold.
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than developing symptoms of initial insomnia among these 
patients (12.6%, 13.1%, and 2.7%, respectively). Among those 
who reported symptoms of insomnia at follow-up, PAP users 
were most likely to report symptoms of late insomnia whereas 
nonusers were more likely to report symptoms of middle 
insomnia (P < 0.05) (Figure 4).
DISCUSSION
The current study shows that insomnia symptoms are 
common among patients with OSA, especially symptoms 
of middle insomnia, and these types of symptoms generally 
improve with PAP treatment. Symptoms of initial insomnia, 
however, tend to persist even though patients adhere to PAP and 
can also negatively affect adherence to PAP treatment. Symp-
toms of late insomnia are (surprisingly) more likely to improve 
among patients with OSA who are PAP nonusers. Furthermore, 
some patients with OSA develop insomnia symptoms over the 
course of treatment. PAP users were more likely to develop 
symptoms of late insomnia whereas the new onset of middle 
insomnia symptoms was more common among nonusers.
The high prevalence of middle insomnia among patients 
with OSA and the indication that these symptoms improve 
significantly with successful PAP treatment suggests that 
symptoms of middle insomnia are a consequence of sleep 
disordered breathing. Our results show that untreated patients 
with OSA with symptoms of isolated middle insomnia are more 
obese and have more severe OSA, which supports this theory. 
This difference in BMI and OSA severity was not present 
for patients with other types of insomnia symptoms. Another 
study examining the relationship between insomnia subtypes 
and daytime sleepiness among patients with OSA also found 
that those with symptoms of middle insomnia had more severe 
OSA as well as increased daytime sleepiness compared with 
patients with symptoms of initial insomnia.5 The increase in 
OSA severity among nonusers could therefore possibly cause 
symptoms of middle insomnia in some patients. The fact that 
nonusers who had no insomnia at baseline were most likely to 
develop symptoms of middle insomnia over the study period 
supports this idea.
In the current study, we saw that patients with symptoms of 
isolated middle insomnia were more likely to adhere to PAP 
treatment. A possible explanation is that patients who are waking 
up frequently during the night while untreated may experience 
relief both from OSA and insomnia symptoms while being 
treated with PAP and therefore adjust favorably to the treat-
ment. Conversely, it seems that other mechanisms contribute to 
symptoms of initial and late insomnia in these patients. Given 
the negative effects of these subtypes of insomnia on PAP 
adherence and the indication that these patients do not experi-
ence relief from their insomnia despite PAP treatment suggests 
that some additional intervention is necessary.
We are aware of only one previous study that evaluated the 
association between insomnia subtypes and PAP adherence. 
Wickwire et al.14 conducted a retrospective medical record review 
of 232 patients with OSA and found that only symptoms of middle 
insomnia predicted poor adherence to PAP,14 which contradicts 
our findings. This discrepancy could partly be explained by the 
different methods performed, in our study  the insomnia assess-
ment was performed at both baseline and follow-up.
Interestingly, symptoms of late insomnia were more likely 
to improve among nonusers in comparison with PAP users. In 
general, sleep is not as sound early in the morning as in the 
beginning of the night when delta sleep is dominant.21,22 Because 
of this, patients may be more likely to wake up because of envi-
ronmental noises, light, or the need to use the bathroom early in 
the morning. Patients who are using PAP may therefore become 
more aware of their device when their sleep gets lighter in the 
morning and for some patients this may disrupt their sleep and 
cause persistence of late insomnia symptoms. This could also 
explain why PAP users who had no insomnia at baseline were 
most likely to develop symptoms of late insomnia. The fact that 
13.1% of them had new onset of late insomnia symptoms is 
noteworthy, especially because the overall prevalence of these 
symptoms among patients with OSA in this study is not nearly 
as high as symptoms of middle insomnia, for example.
This study had a number of strengths including the large 
sample size, the length of the follow-up period, the high response 
rate at follow-up (> 90%), the use of standardized and validated 
procedures and instruments, and most importantly being by 
far the largest study that has looked prospectively at insomnia 
symptoms among patients with OSA before and following PAP 
treatment. In addition, this is a clinical sample with various 
comorbidities, representing the entire spectrum of patients with 
OSA. Our results have important clinical implications and high-
light the need for more studies on additional treatment interven-
tions for patients with OSA and comorbid insomnia.
This study is not, however, without limitations. First, the 
insomnia definition was based on three questions from the Basic 
Nordic Sleep Questionnaire describing symptoms; having more 
detailed questions on insomnia would have been beneficial. 
However, the definitions we used proved to be very instructive 
in the context of OSA and we have a previous publication using 
the same definitions of insomnia.2 Although the 2-y follow-up 
is a strength of the study, evaluating the long-term effects of 
PAP treatment, it can also be considered a limitation. We did not 
have short-term follow-up results to evaluate the acute effects of 
Figure 4—Insomnia status (%) at follow-up among those who had no 
insomnia symptoms at baseline.
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PAP treatment. However, in terms of comparative effectiveness 
research, what matters to patients is not what happens to them 
in 1 mo but over the long term. Because this is a cohort study 
there are many factors that can change in the 2-y study period 
that may affect insomnia other than the use of PAP treatment. 
Second, it would have been beneficial to have more detailed 
information on those patients with initial and late insomnia 
who stopped using PAP. Did they stop using their device purely 
because of their insomnia or were there some other underlying 
reasons? We did not have objective PAP data for all patients 
but we are confident with the way we estimated PAP use. The 
lack of objective PAP data on all participants prevented our 
inclusion of the AHI on the PAP download, a measure of treat-
ment efficacy, as a covariate in our analyses.23 It is possible 
that the ability of PAP treatment to reduce AHI to clinically 
acceptable levels may affect adherence to treatment. Patient-
reported nonusage at follow-up was consistent with the patient 
PAP register, and the results did not change if those without 
objective PAP data were excluded from the analyses. Finally, 
this is an observational study, not a randomized controlled trial 
(RCT), which may be considered a limitation. However, a RCT 
with such long-term follow-up of severely affected patients 
with OSA would be difficult to perform for ethical reasons. 
The importance of observational studies was highlighted in a 
recent publication of a National Institutes of Health workshop 
on comparative effectiveness research.24
To summarize, our results show approximately 50% reduc-
tion in middle insomnia following 2 y of PAP treatment, which 
suggests that frequent awakenings are a symptom of untreated 
OSA. Initial and late insomnia, however, did not improve on 
PAP treatment and these symptoms may negatively affect PAP 
adherence. These results suggest that initial and late insomnia 
in patients with OSA are comorbid but unrelated disorders and 
highlight the importance of including assessment of insomnia 
subtypes in the management of OSA. Future studies should 
focus on exploring the benefits of additional interventions 
prior to or during PAP for patients with OSA and insomnia. 
For example, it may be useful to undertake a trial of cognitive 
behavioral treatment for insomnia (CBT-I) prior to or during 
treatment with PAP to assess whether this intervention not only 
improves the insomnia in the context of OSA, but whether such 
treatment increases compliance with PAP, especially in cases 
of initial and late insomnia. This said, symptoms of initial and/
or late insomnia may be undiagnosed advanced sleep phase 
syndrome or delayed sleep phase syndrome. In these instances, 
CBT-I may be less helpful and chronotherapeutic strategies 
may be more useful.
ABBREVIATIONS
AHI, apnea hypopnea index
BMI, body mass index
BPAP, bilevel pressure
CPAP, continuous positive airway pressure
EDS, excessive daytime sleepiness
ESS, Epworth sleepiness scale
ICC, intraclass correlation coefficient
ISAC, Icelandic sleep apnea cohort
ODI, oxygen desaturation index
OR, odds ratio
OSA, obstructive sleep apnea
PAP, positive airway pressure
SF-12, short form 12
SF-12 MS, short form 12 mental score
SF-12 PS, short form 12 physical score
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